Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 4/20 | 0.39 |
| ▸ | ATM | Q13315 | 5/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | KIF18A | Q8NI77 | 5/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997931 | 0.86 | SMN1; SMN2 (0.42) | ATMAPOBEC3AAPOBEC3GPIK3CA | |
| SCHEMBL21997345 | 0.86 | SMN1; SMN2 (0.42) | ATMAPOBEC3AAPOBEC3GPIK3CA | |
| SCHEMBL21998305 | 0.86 | SMN1; SMN2 (0.42) | ATMAPOBEC3AAPOBEC3GPIK3CA | |
| SCHEMBL21996998 | 0.82 | KMO (0.50) | APOBEC3AAPOBEC3GPIK3CAPIK3CB | |
| SCHEMBL21997553 | 0.79 | SMPD3 (0.42) | APOBEC3AAPOBEC3G | |
| SCHEMBL21996816 | 0.79 | SMPD3 (0.42) | APOBEC3AAPOBEC3G | |
| SCHEMBL21997071 | 0.78 | APOBEC3A (0.44) | APOBEC3AAPOBEC3G | |
| SCHEMBL21998149 | 0.78 | KMO (0.46) | APOBEC3AAPOBEC3GPIK3CAPIK3CB | |
| SCHEMBL25339261 | 0.78 | APOBEC3A (0.47) | APOBEC3AAPOBEC3G | |
| SCHEMBL25338105 | 0.78 | APOBEC3A (0.47) | APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NR3C2 3415/4885PIK3CD 321/4885PIK3CG 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.